Alamar Biosciences announced that its NULISA platform was prominently featured in over 140 scientific presentations at the 2026 Alzheimer's Association International Conference (AAIC) in London, highlighting its growing adoption in Alzheimer's research. The company showcased new data on eMTBR-Tau and BD-pTau217 biomarkers, which improve early detection and disease staging by analyzing multiple proteins simultaneously. This advancement could lead to more precise and earlier Alzheimer's diagnosis, with further insights expected from Alamar's upcoming AAIC workshop. The platform's sensitivity surpasses current market technologies, positioning Alamar as a leader in precision proteomics for neurodegenerative diseases.
Institutional investors are favoring spot Bitcoin and Ethereum ETFs like BlackRock IBIT and Fidelity FBTC, driving steady inflows that support Bitcoin's price around $64,119 and Ethereum near $1,897. This trend highlights a preference for lower-fee, ...
The Monad Foundation's $60 million liquidity program, aimed at reducing selling pressure by allowing early investors to sell locked MON tokens at a discount, was largely rejected as most investors chose to hold their tokens. While this could suggest ...
Zcash (ZEC) has unexpectedly broken out of its recent consolidation, driven by a bullish golden EMA crossover around $495 while trading near $509. This technical signal suggests increased intermediate momentum, supported by strong long-term support l...
Long-term U.S. Treasury yields surged to their highest levels in over two decades due to ongoing tensions between the U.S. and Iran, with the 30-year yield nearing 5.322% and the 10-year yield at 4.736%. Rising geopolitical risks, including Iran's re...
World Liberty Financial (WLFI), backed by the Trump family, is financially supporting WorldClaw, a Hong Kong AI platform using Chinese AI models flagged by the US Pentagon for military ties. WLFI's USD1 stablecoin is used for payments on WorldClaw, c...
